Latest News Releases From The Newsroom
Byrna's Q2 Results Disappoint, electroCore Expects Upbeat Q2 Revenue
July 11th, 2023
Byrna Technologies Inc. (Nasdaq: BYRN) reported a second-quarter fiscal 2023 loss of $0.05 per share and revenue of $11.51 million. These figures fell short of the consensus estimate, which projected earnings per share of $0.01 on revenue of $12 mill. Read more
R100 Vector Deal Fuels 4DMT; ADC Therapeutics Tumbles On ZYNLONTA Trial Status
July 11th, 2023
Astellas Pharma Inc. and 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT)(4DMT) have entered into a license agreement, allowing the use of 4DMT's intravitreal retinotropic R100 vector for rare monogenic ophthalmic diseases. This includes one initial ge. Read more
AspyreRx's Approval Boosts Better Therapeutics; Financial Figures, Outlook Drive WD-40, E2open
July 11th, 2023
Shares of Better Therapeutics, Inc. (Nasdaq: BTTX) surged over 20% in after-hours trading as the company received authorization from the FDA for its groundbreaking prescription-only digital therapeutic, AspyreRx. This innovative treatment offers cogn. Read more
CalAmp Posts Loss, Eyes Strategic Options; PriceSmart Posts Mixed Financial Figures
July 10th, 2023
CalAmp Corp. (Nasdaq: CAMP) faced a first-quarter fiscal 2024 loss of $0.11 per share, falling short of the consensus earnings per share estimate of $0.04. Looking ahead, the company expects Q2 FY24 revenues to range between $67 million and $73 mi. Read more
Market Surges: Mobilicom and Novavax See Dramatic Upswing
July 10th, 2023
Shares of Mobilicom Limited (Nasdaq: MOB) climbed over 100% in early trade following the company's announcement of a significant commercial-scale purchase order from Teledyne-FLIR, one of its Tier-1 customers. The purchase order from Teledyne Tech. Read more
Market Turmoil: FMC Slumps on Lowered Revenue Outlook
July 10th, 2023
Shares of FMC Corporation (NYSE: FMC) plummeted over 6% following the release of an update on its second quarter and full-year 2023 outlook. The company now expects second-quarter revenue to be in the range of $1.00 billion to $1.03 billion, signific. Read more
Helen of Troy Beats Estimates; Analysts Take Note of CAVA Group
July 10th, 2023
Helen of Troy Limited (Nasdaq: HELE) reported first-quarter fiscal 2024 adjusted earnings per share (EPS) of $1.94, surpassing the consensus estimate of $1.60. Looking ahead, for the full-year fiscal 2024, the company expects adjusted EPS to fall . Read more
Q2: NanoString and ASE Technology Unveil Financial Figures
July 10th, 2023
NanoString Technologies, Inc. (Nasdaq: NSTG) has reported strong preliminary financial figures for the second quarter of 2023. The company expects Q2 revenue to surpass $44 million, reflecting a remarkable year-on-year growth of approximately 37%. Th. Read more
Nanobiotix Skyrockets On Multi-Million Dollar NBTXR3 Deal
July 10th, 2023
Shares of Nanobiotix S.A. (Nasdaq: NBTX) surged over 50% in pre-market trading following the announcement of a global licensing and commercialization agreement with Janssen Pharmaceutica NV, a subsidiary of Johnson & Johnson (NYSE: JNJ). The agree. Read more
Earnings Preview: MillerKnoll, AngioDynamics, and Theratechnologies
July 09th, 2023
On Wednesday, July 12, several companies are expected to report their financial results, including: MillerKnoll, Inc. (Nasdaq: MLKN), a consumer goods company, is set to release its financial results for the fourth quarter and full-year fiscal 202. Read more
Want To Find Some News?
News By Industries
Recent Posts
-
Countdown to Earnings: Nutanix, CrowdStrike, and Synopsys on Deck
August 23rd, 2026Investors Eye Semtech, Intuit, and nCino as Earnings Loom
August 22nd, 2026FTC Files Amicus Brief to Protect Competition in Biologic Drug Markets
August 21st, 2026




Member Login